Document is current

Article History

Received: 16 December 2024

Accepted: 5 May 2025

First Online: 27 May 2025

Declarations

:

: This study adhered to the 2022 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS2), which outlines ethical treatment of human participants in Canadian research funded through three federal agencies - the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), and the Social Sciences and Humanities Research Council of Canada (SSHRC). The TCPS2 is maintained by the Panel on Research Ethics and is aligned to the 2021 Tri-Agency Framework: Responsible Conduct of Research (2021), which outlines guidelines for maintaining research integrity throughout the research process. Research reported in this manuscript was conducted in accordance with the Declaration of Helsinki. This study received ethical approval according to TCPS2 from Public Health Ontario’s Ethics Review Board (PHO ERB) on April 5, 2024. Approval for an amended submission was received on September 12, 2024. Consent for data collection was provided at the time of vaccination and was recorded within COVaxON. The need for consent to participate in this study was waived for all study participants (including those younger than 16 years of age) by PHO ERB in alignment with Article 3.7 A of TCPS2, which outlines alterations to consent for projects that pose minimal risk and only include secondary analysis of de-identified health data.

: Not applicable.

: The authors declare no competing interests.